# Cannabinoid and opioid modulation of descending pain circuits in chronic pain

> **NIH NIH R01** · OREGON HEALTH & SCIENCE UNIVERSITY · 2021 · $401,703

## Abstract

PROJECT SUMMARY
 There is now increasing evidence that pathological pain states are dependent on
changes in the brain itself. Descending modulatory pathways are known to mediate top-
down regulation of nociceptive processing, transmitting cortical and limbic influences to the
dorsal horn of the spinal cord. Ascending pain transmission pathways are also intimately
intertwined with these modulatory systems, forming positive and negative feedback loops.
The output node of the best-characterized pain-modulating system is the rostral
ventromedial medulla (RVM). Building on the Heinricher laboratory's experience defining
the outputs of RVM neurons, the studies in the present application fill an important gap,
identifying a pathway through which noxious input reaches the RVM. The RVM has two
pain-modulating cell types: “ON-cells,” which exert a net facilitating influence on nociception,
and “OFF-cells,” which have a net inhibitory action. The overarching goals of the present
proposal are to understand plasticity of this circuitry in chronic pain states, and how it is
modulated by endogenous opioids and cannabinoids. We recently showed that the
parabrachial complex (PB) is a critical relay of acute noxious information to the RVM. We
propose to test the role of the PB in regulating the activity of RVM pain-modulating neurons,
elucidate how opioids and cannabinoids modulate the activity of PB-RVM synapses, and
determine how this connection is altered in chronic pain states. These studies will use in
vivo single-cell recording from identified RVM ON- and OFF-cells, optogenetics, and
pharmacological manipulations to test the hypothesis that the PB projection to the RVM is
modulated following persistent inflammation (Aim 1). Complementing this in vivo work,
parallel studies under Aims 2 and 3 will use in vitro electrophysiology in an adult RVM slice
with optogenetic manipulation of identified PB-RVM terminals to define the membrane
mechanisms of PB-RVM synapses and understand how these synapses are modulated by
cannabinoids and opioids. We will also determine how this connection is altered in chronic
inflammation. By defining pathways through which noxious information reaches pain-
modulating neurons at the membrane, individual neuron, and circuit level, we can begin to
define how pain-modulating circuits are recruited in acute and chronic pain. This information
is critical if we are ever to develop treatments addressing chronic pain as maladaptive brain
disease.

## Key facts

- **NIH application ID:** 10140317
- **Project number:** 5R01DA042565-05
- **Recipient organization:** OREGON HEALTH & SCIENCE UNIVERSITY
- **Principal Investigator:** Mary Magdalen Heinricher
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $401,703
- **Award type:** 5
- **Project period:** 2017-07-01 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10140317

## Citation

> US National Institutes of Health, RePORTER application 10140317, Cannabinoid and opioid modulation of descending pain circuits in chronic pain (5R01DA042565-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10140317. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*